47,541 results match your criteria Human Papillomavirus


Virome analysis of ticks in Zhoushan Archipelago, China.

J Vet Med Sci 2022 May 17. Epub 2022 May 17.

Chinese People's Liberation Army Center for Disease Control and Prevention.

Ticks are an important group of arthropod vectors. Ticks pose a profound risk to public health by transmitting many types of microorganisms that are human and animal pathogens. With the development of next-generation sequencing (NGS) technology and viral metagenomics, numerous novel viruses have been discovered in ticks and tick-related hosts. Read More

View Article and Full-Text PDF

Decreased CD1a + and CD83 + cells in tonsillar squamous cell carcinoma regardless of HPV status.

J Appl Oral Sci 2022 16;30:e20210702. Epub 2022 May 16.

Universidade Federal de Santa Catarina - UFSC, Departamento de Patologia, Florianópolis, SC, Brasil.

Background: Dendritic cells (DCs) are specialized antigen-presenting cells that play a critical role in the immune response against human papillomavirus (HPV) infection, and represent a therapeutic target in cancer.

Objective: To identify and quantify DCs in tonsillar squamous cell carcinoma (TSCC) under the influence of HPV infection.

Methodology: CD1a and CD83 antibodies were used to identify immature dendritic cells and mature dendritic cells by immunohistochemistry in 33 primary TSCC and 10 normal tonsils (NTs), respectively. Read More

View Article and Full-Text PDF

Association between human papillomavirus and urothelial carcinoma of the bladder.

Authors:
Mehmet Sarier

Rev Assoc Med Bras (1992) 2022 May;68(5):551-552

Istinye University, Department of Urology - Istanbul, Turkey.

View Article and Full-Text PDF

Lead-start isothermal polymerase amplification controlled by DNAzymatic switches.

Nanoscale 2022 May 18. Epub 2022 May 18.

Department of Materials Science and Engineering, Pohang University of Science and Technology (POSTECH), Pohang, 37673, South Korea.

As DNA polymerases are even active at ambient temperature, there is inevitable non-specific amplification; to avoid the undesired amplification of analytes, a heat activation-based polymerase chain reaction (PCR), called hot-start PCR, is widely used to be highly precise and quantitative in detection. Unlike thermocycling amplification, isothermal amplification, compatible for point-of-care (PoC) tests, cannot be benefited by the heat-activation technique, making the method qualitative rather than quantitative. In this work, we newly developed a lead ion (Pb) activation technique, called lead-start isothermal amplification, allowing on-demand activation or deactivation of DNA polymerases at room temperature. Read More

View Article and Full-Text PDF

The role of primary care Nurse Practitioners in reducing barriers to cervical cancer screening: A literature review.

Can Oncol Nurs J 2022 1;32(2):233-244. Epub 2022 Apr 1.

Assistant Professor, Faculty of Nursing - University of New Brunswick, Fredericton, New Brunswick.

Nearly all cases of cervical cancer (CC) are caused by persistent infection by human papillomavirus (HPV). CC remains the second most prevalent carcinoma among women and, in 2017, Canada's screening rates were off target by 19%. For example, screening rates as low as 57. Read More

View Article and Full-Text PDF

Radiotherapy and the cellular DNA damage response: current and future perspectives on head and neck cancer treatment.

Cancer Drug Resist 2020 17;3(4):775-790. Epub 2020 Sep 17.

Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool L3 9TA, United Kingdom.

Incidences of head and neck squamous cell carcinoma (HNSCC) have been on the rise in the last few decades, with a significant risk factor being human papillomavirus (HPV) type-16/18 infection, particularly in the development of oropharyngeal cancers. Radiotherapy (RT) is an important treatment modality for HNSCC, where it promotes extensive cellular DNA damage leading to the therapeutic effect. It has been well-established that HPV-positive HNSCC display better response rates and improved survival following RT compared to HPV-negative HNSCC. Read More

View Article and Full-Text PDF
September 2020

Clinical validation of full HR-HPV genotyping HPV Selfy assay according to the international guidelines for HPV test requirements for cervical cancer screening on clinician-collected and self-collected samples.

J Transl Med 2022 05 17;20(1):231. Epub 2022 May 17.

Cervical Cancer Screening Coordination Unit, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy.

Background: According to international guidelines, Human Papillomavirus (HPV) DNA tests represent a valid alternative to Pap Test for primary cervical cancer screening, provided that they guarantee balanced clinical sensitivity and specificity for cervical intraepithelial neoplasia grade 2 or more (CIN2+) lesions. The study aimed to assess whether HPV Selfy (Ulisse BioMed - Trieste, Italy), a full-genotyping HPV DNA test that detects and differentiates 14 high-risk HPV (HR-HPV) types, meets the criteria for primary cervical cancer screening described in the international guidelines, on clinician-collected as well as on self-collected samples.

Methods: For each participant woman, consecutively referring to Azienda Sanitaria Universitaria Giuliano Isontina (Trieste, Italy) and CRO-National Cancer Institute (Aviano, Italy) for the cervical cancer screening program, the following samples were tested: (a) a clinician-collected cervical specimen, analyzed with the reference test (Hybrid Capture®2 test, HC2) and HPV Selfy; and (b) a self-collected vaginal sample, analyzed with HPV Selfy. Read More

View Article and Full-Text PDF

Cervicovaginal loads of spp. are increased in immunocompetent women with persistent high-risk human papillomavirus infection.

J Med Microbiol 2022 May;71(5)

Department of Pathology, Botucatu Medical School, UNESP, São Paulo State University, São Paulo, Brazil.

Two high-oncogenic-risk human papilomavirus (hrHPV) genotypes - HPV16 and HPV18 - cause most of the cases of cervical cancer worldwide. Bacterial vaginosis is associated with increased hrHPV persistence, although the mechanism underlying this association remains unclear. spp. Read More

View Article and Full-Text PDF

Performance of HPV E6/E7 mRNA Assay as Primary Screening Test. Results from the NTCC2 Trial.

Int J Cancer 2022 May 17. Epub 2022 May 17.

IRCCS - Regina Elena National Cancer Institute, Rome, Italy.

As the primary screening test, E6/E7 mRNA has shown similar sensitivity for CIN3+ and lower positivity rate than the HPV DNA test. Nevertheless, the overall mRNA positivity is too high for immediate colposcopy, making a triage test necessary. The aim was to estimate the mRNA performance as a primary test with different triage strategies. Read More

View Article and Full-Text PDF

Results of the George Washington University cancer center's comprehensive cancer control cancer communication mentorship program and implications for future practice.

Cancer Causes Control 2022 May 17. Epub 2022 May 17.

GW Cancer Center, School of Medicine and Health Sciences, The George Washington University, 800 22nd Street NW, Suite 8000, Washington, DC, 20052, USA.

Purpose: The Comprehensive Cancer Control Cancer Communication Mentorship Program ("Mentorship Program") was created by the George Washington University Cancer Center (GWCC) to provide technical assistance (TA) in implementing evidence-based cancer screening communication interventions and support networking for comprehensive cancer control (CCC) professionals. The Mentorship Program matched entry-to mid-level CCC professionals with health communication and/or CCC experts and offered monthly web-based discussions with academic researchers and practitioners who shared their knowledge and provided applied learning opportunities throughout mentees' project planning, implementation and evaluation. The program objective was for mentees to improve health communication skills and apply evidence-based knowledge to reduce the burden of cancer. Read More

View Article and Full-Text PDF

Reply to Wang et al., "Assessment of the Abundance and Potential Function of Human Papillomavirus Type 16 Circular E7 RNA".

mBio 2022 May 17:e0075822. Epub 2022 May 17.

Tumor Virus RNA Biology Section, HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland, USA.

View Article and Full-Text PDF

Assessment of the Abundance and Potential Function of Human Papillomavirus Type 16 Circular E7 RNA.

mBio 2022 May 17:e0041122. Epub 2022 May 17.

Quantitative Biomedical Research Center, UT Southwestern Medical Center, Dallas, Texas, USA.

View Article and Full-Text PDF

On the Regulation of NF-κB pathway by HPV Oncoproteins: Are pathway Inhibitors a good Alternative for the Treatment of Cervical Cancer?

Anticancer Agents Med Chem 2022 May 9. Epub 2022 May 9.

División de Inmunología, Centro de Investigación Biomédica de Occidente (CIBO)-Instituto Mexicano del Seguro Social (IMSS), Sierra Mojada No. 800, Col. Independencia, 44340, Guadalajara, Jalisco, Mexico.

Cervical Cancer (CC) is one of the most prevalent cancer-related pathologies in the female population. It is considered the second leading cause of cancer-related deaths in developing countries. The most important etiological factor for the development of CC is the persistent infection with high-risk human papillomavirus. Read More

View Article and Full-Text PDF

Additional parameters to improve the prognostic value of the 8th edition of the UICC classification for human papillomavirus-related oropharyngeal tumors.

Head Neck 2022 May 17. Epub 2022 May 17.

Department of Otorhinolaryngology and Head and Neck Surgery, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands.

Background: The prognostic reliability of the UICC's TNM classification (8th edition) for human papillomavirus (HPV)-positive tonsillar squamous cell carcinomas (TSCCs) compared to the 7th edition was explored, and its improvement by using additional anatomical and nonanatomical parameters.

Methods: One hundred and ten HPV-positive and 225 HPV-negative TSCCs were retrospectively analyzed. Survival was correlated with patient and tumor characteristics (7th and 8th edition UICC TNM classification). Read More

View Article and Full-Text PDF

HPV Vaccination: Does It Have a Role in Preventing Penile Cancer and Other Preneoplastic Lesions?

Semin Oncol Nurs 2022 May 13:151284. Epub 2022 May 13.

Department of Urology, University Hospitals Leuven, Leuven, Belgium. Electronic address:

Objectives: Human papillomavirus (HPV) is the most common sexually transmitted infection globally, which causes nearly all cervix carcinomas and contributes to oropharyngeal, penile, vulva, vagina, and anal cancers. Despite the role of HPV in several preneoplastic and cancerous lesions in men, male vaccine coverage is low. This article aims to provide insights into the pathophysiology of HPV-related penile cancer and penile intraepithelial neoplasia (PeIN). Read More

View Article and Full-Text PDF

Increases in human papillomavirus vaccine coverage over 12 months among a community-recruited cohort of gay, bisexual, and other men who have sex with men in Canada.

Vaccine 2022 May 13. Epub 2022 May 13.

University of Toronto, Toronto, Ontario, Canada; Unity Health Toronto, Toronto, Ontario, Canada. Electronic address:

Background: Starting in 2015/16, most Canadian provinces introduced publicly-funded human papillomavirus (HPV) vaccination programs for gay, bisexual, and other men who have sex with men (GBM) aged ≤ 26 years. We estimated 12-month changes in HPV vaccine coverage among community-recruited GBM from 2017 to 2021 and identified baseline factors associated with vaccine initiation (≥1 dose) or series completion (3 doses) among participants who were unvaccinated or partially vaccinated at baseline.

Methods: We recruited sexually-active GBM aged ≥ 16 years in Montreal, Toronto, and Vancouver, Canada, from 02/2017 to 08/2019 and followed them over a median of 12 months (interquartile range = 12-13 months). Read More

View Article and Full-Text PDF

Efficacy and safety of photodynamic therapy mediatied by 5-aminolevulinic acid for the treatment of vaginal high-grade intraepithelial lesions.

Photodiagnosis Photodyn Ther 2022 May 13:102899. Epub 2022 May 13.

Department of Obstetrics and Gynecology, Peking University Third Hospital.

Background: Vaginal high-grade squamous intraepithelial lesion (HSIL) (vaginal intraepithelial neoplasia [VAIN] grade 2-3) is a clinical precancerous lesion condition with an estimated progression rate of 10%-20%. Therefore, treatment is recommended. Because traditional treatments have limited effects or high expenses or complications, here we evaluated the efficacy and safety of topical 5-aminolevulinic acid (ALA)-based photodynamic therapy (PDT). Read More

View Article and Full-Text PDF

Human Papillomavirus Vaccine Impact and Effectiveness Through 12 Years After Vaccine Introduction in the United States, 2003 to 2018.

Ann Intern Med 2022 May 17. Epub 2022 May 17.

Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia (J.W.G., L.E.M.).

Background: Human papillomavirus (HPV) vaccination was introduced in 2006 for females and in 2011 for males.

Objective: To estimate vaccine impact and effectiveness against quadrivalent HPV vaccine (4vHPV)-type prevalent infection among sexually experienced U.S. Read More

View Article and Full-Text PDF

Long-Term Effectiveness of Human Papillomavirus Vaccination: Implications for Future Reduction in Cancer.

Ann Intern Med 2022 May 17. Epub 2022 May 17.

Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, New York.

View Article and Full-Text PDF

Computer-Animated Relational Agents in Human Papillomavirus Vaccination Education.

Obstet Gynecol 2022 May 5;139(5):913-915. Epub 2022 Apr 5.

Division of Gynecologic Oncology, Department of Oncology, the Department of Obstetrics and Gynecology, the Biostatistics and Bioinformatics Core, Karmanos Cancer Institute, Department of Oncology, School of Medicine, and the Behavioral and Field Research Core, Department of Oncology, Wayne State University, and the Wayne State University School of Medicine, Detroit, Michigan; the Thomas Jefferson University College of Population Health and Main Line Health Center for Population Health Research at Lankenau Institute for Medical Research, Philadelphia, Pennsylvania; the Department of Obstetrics and Gynecology, the Department of Family and Preventive Medicine, College of Medicine, and the TSET Health Promotion Research Center, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; and Computer Sciences, Northeastern University, Boston, Massachusetts.

View Article and Full-Text PDF

Utilization and Outcomes of Sentinel Lymph Node Biopsy for Early Endometrial Cancer.

Obstet Gynecol 2022 May 5;139(5):809-820. Epub 2022 Apr 5.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, and the Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California; the Department of Obstetrics and Gynecology, University of Freiburg Faculty of Medicine, Freiburg, Germany; the Section of Urology, University of Chicago Medicine, Chicago, Illinois; and the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, New York.

Objective: To examine trends, characteristics, and oncologic outcomes of sentinel lymph node biopsy for early endometrial cancer.

Methods: This observational study queried the National Cancer Institute's Surveillance, Epidemiology, and End Results Program by examining 83,139 women with endometrial cancer who underwent primary hysterectomy with nodal evaluation for T1 disease from 2003 to 2018. Primary outcome measures were the temporal trends in utilization of sentinel lymph node biopsy and patient characteristics associated with sentinel lymph node biopsy use, assessed by multivariable binary logistic regression models. Read More

View Article and Full-Text PDF

Prevalence and determinants of oral and cervicogenital HPV infection: Baseline analysis of the Michigan HPV and Oropharyngeal Cancer (MHOC) cohort study.

PLoS One 2022 16;17(5):e0268104. Epub 2022 May 16.

Department of Epidemiology, University of Michigan, Ann Arbor, Michigan, United States of America.

We determined baseline oral and cervicogenital human papillomavirus (HPV) prevalence and determinants of infection in the Michigan HPV and Oropharyngeal Cancer (MHOC) study. We enrolled 394 college-age and older participants of both sexes in Ann Arbor, Michigan and the surrounding area. All participants provided an oral sample at baseline, and 130 females provided a cervicogenital sample. Read More

View Article and Full-Text PDF

Molecular Detection Methods in HPV-Related Cancers.

Front Oncol 2022 27;12:864820. Epub 2022 Apr 27.

Division of Otolaryngology-Head and Neck Surgery Research Laboratory of Alberta, Department of Surgery, University of Alberta, Edmonton, AB, Canada.

Human papillomavirus (HPV) is responsible for most cervical cancers and some head and neck cancers, including oropharyngeal squamous cell carcinoma and sinonasal carcinoma. Cervical cancer is commonly diagnosed by liquid-based cytology, followed by HPV testing using commercially available DNA polymerase chain reaction (PCR), p16 immunohistochemistry (IHC), or DNA/RNA hybridization. HPV in head and neck cancers is commonly diagnosed by p16 IHC or by RT-qPCR of HPV-16 E6 and E7 oncoproteins. Read More

View Article and Full-Text PDF

Global online interest in cervical cancer care in the time of COVID-19: An infodemiology study.

Gynecol Oncol Rep 2022 Jun 10;41:100998. Epub 2022 May 10.

College of Medicine, University of the Philippines, Manila, Philippines.

Introduction: Internet search trends may gauge public awareness and interest in cancer and help identify key areas for improvement in public health interventions and awareness campaigns. During the COVID-19 pandemic, cervical cancer screening significantly decreased, and we hypothesized that this would be mirrored by a decreased online interest in cervical cancer care.

Methods: Using the Google Trends database, we analyzed 2018-2021 global search trends in the following topics: cervical cancer, human papillomavirus, HPV vaccine, Cervarix, Gardasil, Pap test, HPV test, and colposcopy. Read More

View Article and Full-Text PDF

Hybrid Model for Detection of Cervical Cancer Using Causal Analysis and Machine Learning Techniques.

Comput Math Methods Med 2022 4;2022:4688327. Epub 2022 May 4.

Division of Information and Computing Technology, College of Science and Engineering, Hamad Bin Khalifa University, Qatar Foundation, Doha, Qatar.

Cervical cancer has become the third most common form of cancer in the in-universe, after the widespread breast cancer. Human papillomavirus risk of infection is linked to the majority of cancer cases. Preventive care, the most expensive way of fighting cancer, can protect about 37% of cancer cases. Read More

View Article and Full-Text PDF

A Recent Advancement In Nanotechnology Approaches For The Treatment Of Cervical Cancer.

Anticancer Agents Med Chem 2022 May 13. Epub 2022 May 13.

Department of Pharmaceutics, Swamy Vivekananda College of Pharmacy, Elayampalayam, Namakkal, Tamilnadu 637205, India.

Background: Cervical cancer is one of the leading causes of female death, with a mortality rate of over 200,000 per year in developing countries. . Despite a decrease in cervical cancer occurrences in developed countries over the last decade, the frequency of the disease in developing nations continues to climb at an alarming rate, particularly when it is linked to the human papillomavirus (HPV). Read More

View Article and Full-Text PDF

A systematic review with meta-analysis of parental interventions for human papillomavirus vaccine uptake.

J Am Pharm Assoc (2003) 2022 Apr 13. Epub 2022 Apr 13.

Objectives: With the growing ability of pharmacists to vaccinate against HPV, this systematic review with meta-analysis examined the efficacy of interventions targeting parents of children and adolescents in the US to increase HPV vaccine uptake.

Data Sources: A systematic search of PubMed, Web of Science, SCOPUS, CINAHL, and Medline was conducted from January 2006 to January 2022.

Study Selection: We included parent-based randomized controlled trials (RCTs) in the US that measured actual HPV vaccine initiation and completion from patients' medical records. Read More

View Article and Full-Text PDF

Changes in the cervicovaginal microbiota composition of HPV16-infected patients after clinical treatment.

Cancer Med 2022 May 15. Epub 2022 May 15.

Department of Lab Medicine, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, China.

Background: High-risk human papillomavirus (hrHPV) infection is a key factor that alters cervicovaginal microbiota patterns and causes cervical intraepithelial neoplasias (CINs) or even cervical cancer. Although local excisional treatment can clear hrHPV infection and restore the cervicovaginal microbiota, it is unclear which cervicovaginal microbiota represents recovery. Our objective was to describe the cervicovaginal microbiota before and after treatments and to assess the association between the microbiota and HPV persistence. Read More

View Article and Full-Text PDF

Human papillomavirus vaccination related knowledge, and recommendations among healthcare providers in Southern China: a cross-sectional survey.

BMC Womens Health 2022 May 14;22(1):169. Epub 2022 May 14.

The Research Institute of Maternity and Child Medicine, Affiliated Shenzhen Maternity and Child Healthcare Hospital, Southern Medical University, No. 2004, Hongli Road, Futian District, Shenzhen, 518000, China.

Background: Little research has been conducted to explore variables associated with the healthcare providers' (HCPs) understanding and recommendation of human papillomavirus vaccine (HPV) since the vaccine was approved for use in China.

Methods: A large-scale cross-sectional survey was conducted in southern China covering Guangdong, Guangxi, and Hainan provinces between April 2019 and October 2019. Firstly, descriptive analysis was used to access awareness, knowledge, barriers, and recommendations toward HPV vaccine among all participants. Read More

View Article and Full-Text PDF